Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

176 to 200 of 339 results

Germany's IQWiG confirms Jetrea's added value for VMT patients

02-08-2013

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) announced today (August 2) that the…

BiotechnologyEuropeJetreaOphthalmicsPharmaceuticalPricingRegulationThromboGenics

UK's NICE calls for more data to consider Roche drug for a type of vasculitis

23-07-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

UK's NICE recommends hepatitis C treatment for children

18-07-2013

In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

Negative NICE news for Pfizer leukemia drug

16-07-2013

There was disappointment for global drugs behemoth Pfizer (NYSE: OFE) when the UK drugs watchdog the…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRegulation

IQWiG finds added benefit for Dificlir in C. difficile infections

16-07-2013

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed additional information…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropePharmaceuticalPricingRegulation

First IQWiG assessment of the established drug market finds advantage for Januvia

15-07-2013

There are hints of a minor added benefit of US drug giant Merck & Co's (NYSE: MRK) Januvia (sitagliptin)…

DiabetesEuropeMerck & CoPharmaceuticalPricingRegulation

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

Added benefit of Mitsubishi Tanabe's colestilan not proven, says German IQWiG

10-07-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

BindRencolestilanEuropeMitsubishi TanabeNephrology and HepatologyPharmaceuticalPricingRegulation

Ireland's HSE to reimburse InterMune's Esbriet for IPF

08-07-2013

US biotech firm InterMune's (Nasdaq: ITMN) UK subsidiary says that Ireland's Health Service Executive…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

Proposal for a sole supply arrangement for fentanyl patches in New Zealand

08-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list a…

Asia-PacificfentanylFentanyl SandozNeurologicalNovartisPharmaceuticalPricingRegulationSandoz

Novartis breast cancer drug Afinitor not cost effective for NHS, says draft NICE guidance

08-07-2013

Swiss drug major Novartis' (NOVN: VX) breast cancer drug Afinitor (everolimus) is not recommended as…

AfinitorEuropeNovartisOncologyPharmaceuticalPricingRegulation

Largely negative views from Germany's IQWiG on AstraZeneca's Caprelsa in thyroid cancer

26-06-2013

In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalPricingRegulation

Setback for myelofibrosis patients as UK's NICE rejects Novartis' Jakavi

26-06-2013

Swiss drug major Novartis today (June 26) expressed disappointment at the decision of UK drugs watch…

EuropeJakaviNovartisOncologyPharmaceuticalPricingRegulation

Eisai temporarily suspend Fycompa in Germany, following negative G-BA decision

25-06-2013

Japanese drug major Eisai (TYO: 4523) said today (June 25) that, "with regret," it will suspend temporarily…

EisaiEuropeFycompaMarkets & MarketingNeurologicalPharmaceuticalPricingRegulation

A$5 billion worth of drugs have gained PBS listing in Australia since 2007

24-06-2013

The Labour government in Australia has approved the listing of over A$5 billion ($4.6 billion) worth…

Asia-PacificPharmaceuticalPricingRegulation

UK's NICE issues negative new draft guidance on Sanofi's Zaltrap

21-06-2013

The UK's drug watchdog the National Institute for Health Care and Excellence (NICE) has issued new draft…

EuropeOncologyPharmaceuticalPricingRegulationSanofiZaltrap

NICE says "yes" to Alimera's Iluvien for treatment of diabetic macular edema

14-06-2013

In draft guidance published today (June 14) by UK drugs watch dog the National Institute for Health and…

Alimera SciencesEuropeIluvienOphthalmicsPharmaceuticalPricingRegulation

NICE final draft guidance on Eli Lilly's Alimta negative

13-06-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (June 13)…

AlimtaEli LillyEuropeOncologyPharmaceuticalPricingRegulation

UK's NICE gives thumbs up for GSK's Revolade as NHS blood disorder treatment

12-06-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has published final draft…

EuropePharmaceuticalPricingRegulation

ThromboGenics' Jetrea gets initial NICE recommendation for VMT

12-06-2013

Belgium-based biopharma company ThromboGenics (Euronext Brussels: THR) said this morning (June 12) that…

AlconEuropeJetreaNovartisOphthalmicsPharmaceuticalPricingRegulationThromboGenics

New Zealand to fund AstraZeneca's Brilinta for acute coronary syndromes

10-06-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, says it has reached an agreement with the local…

Asia-PacificAstraZenecaBrilintaCardio-vascularPharmaceuticalPricingRegulation

EU Pharma leaders call for right balance between health care budget and economic growth objectives

10-06-2013

The Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA),…

EuropeFinancialPharmaceuticalPoliticsPricingRegulation

UK's NICE plans to recommend Abilify for children with bipolar disorder

10-06-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued new draft…

AbilifyEuropeLundbeckNeurologicalOtsukaPharmaceuticalPricingRegulation

176 to 200 of 339 results

COMPANY SPOTLIGHT

Menarini

Back to top